Research & Development: MP0310 (FAP x 4-1BB): First patient dosed in phase 1 trial for this tumor-localized immune-modulator, representing a key milestone as the first novel therapeutic design of an immuno-oncology DARPin® candidate in clincial development (in co-development with Amgen) MP0250

Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year   Abicipar sustained vision gains in year two with quarterly injections compared to monthly ranibizumab   Reductions in central

Zurich-Schlieren, Switzerland, October 4, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that its partner Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more

Zurich-Schlieren, Switzerland, October 3, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that the first patient has been enrolled and dosed in a Phase 1 first-in-human study of MP0310 as

Filing includes data from two Phase 3 trials which evaluated the safety and efficacy of Abicipar quarterly dosing regimen Approvals in the United States and Europe are anticipated in 2020 DUBLIN, IRELAND – SEPT 9, 2019  – Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a

Research & Development: MP0250 (VEGF x HGF) in MM: PI Trial (in combination with Velcade®) – Encouraging responses observed in first patient cohorts triggered decision for further investment; IMiD Trial (in combination with Pomalyst®) – Start of phase 2 trial expected in Q4 19, having received FDA

Zurich-Schlieren, Switzerland, August 8, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced the appointment of Nicolas Leupin, M.D., MBA, to the role of Chief Medical Officer and Member of

Zurich-Schlieren, Switzerland, August 6, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that the European Medicines Agency (EMA) has validated the marketing authorisation application

Pamela A. Trail, Ph.D., to transition from Chief Scientific Officer to strategic consultant; Daniel Steiner, Ph.D., to assume leadership of research organization Zurich-Schlieren, Switzerland, June 11, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a

Research & Development: MP0250 (VEGF x HGF) in MM: Additional patient data from ongoing Phase 2 study of MP0250 in combination with Velcade® (PI) support previously observed response rates and duration of treatment MP0250 in combination with osimertinib in EGFR-mutated Non-Small Cell Lung Cancer